×
About 257,418 results
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
https://doi.org/10.1056/NEJMoa1805762
The New England Journal of Medicine; Dimopoulos MA, Dytfeld D et. al.

Nov 7th, 2018 - The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. Patients with multiple myeloma t...

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
https://doi.org/10.1056/NEJMoa1712746
The New England Journal of Medicine; Anderson DR, Dunbar M et. al.

Feb 21st, 2018 - Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge. We performed a multicenter, double-blind, randomized, controlled trial i...

Five-year results of brentuximab vedotin in patients with relapsed or refractory system...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746164
Blood Pro B, Advani R et. al.

Oct 4th, 2017 - This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated o...

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Clas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Chen R, Zinzani PL et. al.

Apr 25th, 2017 - Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifie...

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965
The New England Journal of Medicine; Hochhaus A, Larson RA et. al.

Mar 8th, 2017 - Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed C...

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Gro...
https://doi.org/10.1200/JCO.2016.71.3289
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bröckelmann PJ, Goergen H et. al.

Feb 27th, 2017 - Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. P...

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
https://doi.org/10.1056/NEJMoa1513257
The New England Journal of Medicine; Roberts AW, Davids MS et. al.

Dec 7th, 2015 - New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma...

FDA approves first therapy to treat patients with rare blood disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder
FDA FDA

Nov 9th, 2019 - Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

Diffuse Large B-Cell Lymphoma
https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/
Lymphoma Research Foundation;

Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
https://www.jnj.com/u-s-fda-approves-xarelto-rivaroxaban-to-help-prevent-blood-clots-in-acutely-ill-medical-patients

Oct 13th, 2019 - he Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding. With the approval of this new indication, XAREL...

Anticoagulation: Updated Guidelines for Outpatient Management
https://www.aafp.org/afp/2019/1001/p426.html
American Family Physician;

Sep 30th, 2019 - Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for ...

FDA approves daratumumab for transplant-eligible multiple myeloma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma

Sep 25th, 2019 - On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory evaluation and medical management. Evaluation of adolescent girls who present with heavy men...

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq

Aug 19th, 2019 - Treatments for children with acute myeloid leukemia and myeloid malignancies include combination chemotherapy, stem cell transplantation, and targeted therapy. Other drug therapy and supportive care is also used. Get detailed information for these diseases in this clinician summary.

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval of INREBIC is another important milestone for Celgene and underscores our commitment ...

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
https://ascopubs.org/doi/full/10.1200/JCO.19.01461

Aug 4th, 2019 - PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from August 1, 2014, through December 4, 2018. ASCO convened an Expert Panel to review the evidence and revise previous recommenda...

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies
https://www.mdpi.com/2072-6694/11/8/1174
Cancers Petrelli, F. et. al.

Jul 30th, 2019 - The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequ...

FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market
https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-patients-risk-certain-textured-breast-implants-requests-allergan

Jul 23rd, 2019 - The U.S. Food and Drug Administration today took significant action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by requesting that Allergan, the manufacturer of a specific type of textured implant, recall specific models of its textured breast implants from the U.S. market due to the risk of BIA-ALCL. Following the agency’s request, Allergan has not...

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).2 “Biosimilars like RUXIENCE h...

Bayer Statement on Voluntary Recall of Two Lots of Kogenate FS Antihemophilic Factor (Recombinant) in the United States
https://www.drugs.com/fda/bayer-statement-voluntary-recall-two-lots-kogenate-fs-antihemophilic-factor-recombinant-united-14291.html

Jul 18th, 2019 - Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemophilia A treatment, Jivi antihemophilic factor (recombinant) PEGylated-aucl 3000 IU. The U.S. is the only country where affected products were distribu...